Objective: To investigate the effect of tegileridine fumarate on postoperative analgesia and early recovery quality, as well as its safety, in patients undergoing laparoscopic gastrointestinal tumour surgery. Methods: A retrospective analysis was conducted on 120 patients who underwent laparoscopic gastrointestinal tumour surgery. All patients received postoperative analgesia via patient-controlled intravenous analgesia (PCIA). Based on the different analgesic drugs used, they were divided into an observation group (tegileridine fumarate, n =53) and a control group (sufentanil combined with nalbuphine, n=67). Postoperative pain intensity, serum pain mediator levels, and sleep quality were assessed. Hospital stay duration, hospitalisation costs, and related adverse reactions were also recorded. Results: The VAS scores at 24, 48, and 72 h postoperatively were lower in the observation group than in the control group(P<0.05). At 72 h postoperatively, serum levels of substance P(SP), prostaglandin E2(PGE2), and calcitonin gene-related peptide(CGRP) were lower in the observation group than in the control group(P<0.05). On the day after surgery, the observation group showed better scores than the control group in sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, and total Pittsburgh Sleep Quality Index (PSQI) score(P<0.05). The hospital stay was shorter(P<0.05) and hospitalisation costs were lower(P<0.05) in the observation group compared to the control group. The incidence of postoperative nausea/vomiting and respiratory depression in the observation group was lower than that in the control group (P<0.05). Conclusion: Tegileridine fumarate helps optimise postoperative analgesic effects and early sleep quality in patients undergoing laparoscopic gastrointestinal tumour surgery, shortens hospital stay, reduces hospitalisation costs, and demonstrates a favourable safety profile